Exploring Analyst Estimates for Moderna (MRNA) Q2 Earnings, Beyond Revenue and EPS

Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period. While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights. The consensus estimate for 'Revenue- Product sales' stands at $102.49 million. The estimate indicates ...